Literature DB >> 33428805

Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.

Philip S Boonstra1, Asra Ahmed2, Samuel A Merrill3, Ryan A Wilcox2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33428805      PMCID： PMC8968463          DOI： 10.1002/ajh.26091

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

2.  Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2020-09-30       Impact factor: 10.047

3.  Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Authors:  Elisabet Bergsten; AnnaCarin Horne; Maurizio Aricó; Itziar Astigarraga; R Maarten Egeler; Alexandra H Filipovich; Eiichi Ishii; Gritta Janka; Stephan Ladisch; Kai Lehmberg; Kenneth L McClain; Milen Minkov; Scott Montgomery; Vasanta Nanduri; Diego Rosso; Jan-Inge Henter
Journal:  Blood       Date:  2017-09-21       Impact factor: 22.113

4.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Authors:  Franco Locatelli; Michael B Jordan; Carl Allen; Simone Cesaro; Carmelo Rizzari; Anupama Rao; Barbara Degar; Timothy P Garrington; Julian Sevilla; Maria-Caterina Putti; Franca Fagioli; Martina Ahlmann; Jose-Luis Dapena Diaz; Michael Henry; Fabrizio De Benedetti; Alexei Grom; Genevieve Lapeyre; Philippe Jacqmin; Maria Ballabio; Cristina de Min
Journal:  N Engl J Med       Date:  2020-05-07       Impact factor: 91.245

5.  Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Rupali Das; Peng Guan; Leslee Sprague; Katherine Verbist; Paige Tedrick; Qi Angel An; Cheng Cheng; Makoto Kurachi; Ross Levine; E John Wherry; Scott W Canna; Edward M Behrens; Kim E Nichols
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

6.  A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.

Authors:  Samuel A Merrill; Rakhi Naik; Michael B Streiff; Satish Shanbhag; Sophie Lanzkron; Evan M Braunstein; Alison M Moliterno; Robert A Brodsky
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  6 in total
  3 in total

1.  Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review.

Authors:  Jennifer Croden; Lisa Bilston; Minakshi Taparia; Jennifer Grossman; Haowei Linda Sun
Journal:  Ann Hematol       Date:  2022-08-17       Impact factor: 4.030

Review 2.  Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.

Authors:  Halil Yildiz; Sarah Bailly; Eric Van Den Neste; Jean Cyr Yombi
Journal:  Ther Clin Risk Manag       Date:  2021-04-14       Impact factor: 2.423

3.  Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

Authors:  Xiang Liu; Xueling Zhu; Xiaotang Zhou; Yirui Xie; Dairong Xiang; Zhikai Wan; Ying Huang; Biao Zhu
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.